logo-loader

Faron Pharmaceuticals' Markku Jalkanen presents at the Biotech Capital Conference

Published: 14:59 07 Oct 2016 BST

Faron Pharmaceuticals' Markku Jalkanen presents at the Biotech Capital Conference 

Faron Pharmaceuticals reports promising phase 1 results from BEXMAB study

Faron Pharmaceuticals Limited (AIM:FARN) chief executive Dr Markku Jalkanen joins Proactive's Stephen Gunnion with additional positive data from the Phase 1 study of the ongoing bexmarilimab (BEXMAB) trial that has moved into Phase 2 for higher-risk (HR) myelodysplastic syndrome (MDS) patients...

1 week, 3 days ago